Middle East and Africa Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables and Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research and Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes and Hospital & Clinics), Country (South Africa and Rest of Middle East And Africa) Industry Trends & Forecast to 2029.
Market Analysis and Insights : Middle East and Africa Next Generation Sequencing (NGS) Market
Middle East and Africa next generation sequencing (NGS) market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.7% in the forecast period of 2022 to 2029 and is expected to reach USD 791.18 million by 2029. Increasing research activities next generation sequencing (NGS) act as driver for the next generation sequencing (NGS) market growth.
High-throughput sequencing, most widely regarded as the "next-generation" sequencing (NGS), is now integrated into routine clinical practice due to the numerous technical and functional developments, while early protocols relied on samples harvested outside of typical workflows in clinical pathology, standard formalin-fixed, paraffin-embedded specimens which can be used more regularly as starting material for NGS. In addition, protocols are being amassed for the analysis and interpretation of NGS data, as well as knowledge bases, allowing clinicians to act more easily on genomic information at the patient care point. The presence of wide range of products of the next generation sequencing used in the diagnosis of chronic diseases is satisfying the need of the healthcare facilities. The increased technological advancement leads to development of highly efficient next generation sequencing (NGS) in the market.
Major factors driving the growth of next generation sequencing (NGS) market are use of next generation sequencing in drug development and wide portfolio offered by major player and the factor which hampers the growth of the next generation sequencing (NGS) market includes high cost of next generation sequencing products and product recall.
The next generation sequencing (NGS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the next generation sequencing (NGS) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Next Generation Sequencing (NGS) Market Scope and Market Size
The next generation sequencing (NGS) market is segmented on basis of product, applications, end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the Middle East and Africa next generation sequencing (NGS) market is segmented into instrument, consumables, and services. In 2022, instrument segment is dominating the next generation sequencing (NGS) market as the companies are trying to expand their business to through sales of products in these regions which is acting as the reason for dominance.
- On the basis of application, the Middle East and Africa next generation sequencing (NGS) market is segmented into diagnostic, drug discovery, biomarker discovery, precision medicine, agriculture and animal research. In 2022, the diagnostic segment is dominating the Middle East and Africa next generation sequencing (NGS) market due to the fact that the prevalence of disease is high in these regions and the use of NGS in diagnosis is low in these countries
- On the basis of end user, the Middle East and Africa next generation sequencing (NGS) market is segmented into hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies. In 2022, research center and academic & government institutes is dominating in the Middle East and Africa next generation sequencing (NGS) market as the research on the companies has collaborated with African institutes which has knowledge of African gene which dominate the segment
Next Generation Sequencing (NGS) Market Country Level Analysis
The next generation sequencing (NGS) market is analyzed and market size information is provided by the country, product, application, and end user as referenced above.
The countries covered in the next generation sequencing (NGS) market report are South Africa and rest of Middle East and Africa.
Diagnostic segment in South Africa of the region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of use of next generation technology in hospitals and clinics.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Next generation sequencing (NGS) Treatment, is Boosting the Market Growth of Next generation sequencing (NGS) market.
The next generation sequencing (NGS) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.
Competitive Landscape and Next Generation Sequencing (NGS) Market Share Analysis
Next generation sequencing (NGS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to next generation sequencing (NGS) market.
Some of the major companies which are dealing in the next generation sequencing (NGS) are Agilent Technologies, Inc., ThermoFisher Scientific, Inc., QIAGEN, Illumina, Inc., Bio-Rad Laboratories, Inc., Roche Sequencing (A subsidiary of F. Hoffman La Roche), BGI (A subsidiary of BGI Group), Oxford Nanopore Technologies plc, MACROGEN CO., LTD., DNASTAR, Geneious, Partek, Incorporated, PerkinElmer Inc., Takara Bio Inc., bioMérieux SA, among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the next generation sequencing (NGS) market.
For instance,
- In February 2021, Thermo Fisher Scientific Inc. announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company’s footprints in Middle East and Africa market and leading to upsurgecompany’s growth in the coming years.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the next generation sequencing (NGS) market which also provides the benefit for organization’s profit growth.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PESTEL'S ANALYSIS
3.2 PORTER'S FIVE FORCES MODEL
4 REGULATIONS OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 DECREASE IN THE COST OF GENETIC SEQUENCING PER BASE
5.1.2 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY
5.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER
5.1.4 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT
5.1.5 INCREASED TREND TOWARDS PERSONALIZED MEDICATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENT
5.2.2 DIFFICULTY IN CLINICAL NGS DATA ANALYSIS
5.2.3 CYBER SECURITY CONCERN IN GENOMICS
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
5.3.2 PRODUCT APPROVAL IN RECENT YEARS
5.3.3 ADVANCEMENT IN NGS TECHNOLOGY
5.4 CHALLENGES
5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS
5.4.2 CHALLENGES FOR IMPLEMENTING NGS IN THE CLINICAL LAB
6 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) HEALTHCARE INDUSTRY
6.1 IMPACT ON PRICE
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 HISEQ SERIES
7.2.2 MISEQ SERIES
7.2.3 ION TORRENT
7.2.4 PACBIO RS II
7.2.5 SEQUEL SYSTEM
7.2.6 SOLID
7.2.7 OTHERS
7.3 CONSUMABLE
7.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
7.3.2 SAMPLE PREPARATION CONSUMABLES
7.3.3 OTHERS
7.4 SERVICES
7.4.1 SEQUENCING SERVICES
7.4.2 DATA MANAGEMENT
8 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTICS
8.3 BIOMARKER DISCOVERY
8.4 PRECISION MEDICINE
8.5 DRUG DISCOVERY
8.6 AGRICULTURE & ANIMAL RESEARCH
9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES
9.4 HOSPITAL & CLINICS
10 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION
10.1 MIDDLE EAST AND AFRICA
10.1.1 SOUTH AFRICA
10.1.2 REST OF MIDDLE EAST AND AFRICA
11 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 COMPANY PROFILING
12.1 ILLUMINA, INC.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 SWOT ANALYSIS
12.1.5 PRODUCT PORTFOLIO
12.1.6 RECENT DEVELOPMENTS
12.2 BGI (A SUBSIDIAIRY OF BGI GROUP) (2021)
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 SWOT ANALYSIS
12.2.5 PRODUCT PORTFOLIO
12.2.6 RECENT DEVELOPMENT
12.3 THERMO FISHER SCIENTIFIC INC.
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 SWOT ANALYSIS
12.3.5 PRODUCT PORTFOLIO
12.3.6 RECENT DEVELOPMENTS
12.4 QIAGEN
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 SWOT ANALYSIS
12.4.5 PRODUCT PORTFOLIO
12.4.6 RECENT DEVELOPMENTS
12.5 AGILENT TECHNOLOGIES, INC.
12.5.1 COMPANY SNAPSHOT
12.5.2 REVENUE ANALYSIS
12.5.3 COMPANY SHARE ANALYSIS
12.5.4 SWOT ANALYSIS
12.5.5 PRODUCT PORTFOLIO
12.5.6 RECENT DEVELOPMENT
12.6 OXFORD NANOPORE TECHNOLOGIES
12.6.1 COMPANY SNAPSHOT
12.6.2 PRODUCT PORTFOLIO
12.6.3 RECENT DEVELOPMENTS
12.7 BIO-RAD LABORATORIES, INC.
12.7.1 COMPANY SNAPSHOT
12.7.2 REVENUE ANALYSIS
12.7.3 PRODUCT PORTFOLIO
12.7.4 RECENT DEVELOPMENTS
12.8X GENOMICS
12.8.1 COMPANY SNAPSHOT
12.8.2 REVENUE ANALYSIS
12.8.3 PRODUCT PORTFOLIO
12.8.4 RECENT DEVELOPMENTS
12.9 BIOMÉRIEUX SA
12.9.1 COMPANY SNAPSHOT
12.9.2 REVENUE ANALYSIS
12.9.3 PRODUCT PORTFOLIO
12.9.4 RECENT DEVELOPMENT
12.1 DNASTAR
12.10.1 COMPANY SNAPSHOT
12.10.2 PRODUCT PORTFOLIO
12.10.3 RECENT DEVELOPMENT
12.11 GENEIOUS
12.11.1 COMPANY SNAPSHOT
12.11.2 PRODUCT PORTFOLIO
12.11.3 RECENT DEVELOPMENTS
12.12 GENEWIZ, FROM AZENTA LIFE SCIENCES
12.12.1 COMPANY SNAPSHOT
12.12.2 REVENUE ANALYSIS
12.12.3 PRODUCT PORTFOLIO
12.12.4 RECENT DEVELOPMENTS
12.13 HAMILTON COMPANY
12.13.1 COMPANY SNAPSHOT
12.13.2 PRODUCT PORTFOLIO
12.13.3 RECENT DEVELOPMENT
12.14 MACROGEN, INC.
12.14.1 COMPANY SNAPSHOT
12.14.2 REVENUE ANALYSIS
12.14.3 PRODUCT PORTFOLIO
12.14.4 RECENT DEVELOPMENT
12.15 NEW ENGLAND BIOLABS
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENT
12.16 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
12.16.1 COMPANY SNAPSHOT
12.16.2 REVENUE ANALYSIS
12.16.3 PRODUCT PORTFOLIO
12.16.4 RECENT DEVELOPMENTS
12.17 PARTEK, INCORPORATED
12.17.1 COMPANY SNAPSHOT
12.17.2 PRODUCT PORTFOLIO
12.17.3 RECENT DEVELOPMENT
12.18 PERKIN ELMER INC. (2021)
12.18.1 COMPANY SNAPSHOT
12.18.2 REVENUE ANALYSIS
12.18.3 PRODUCT PORTFOLIO
12.18.4 RECENT DEVELOPMENTS
12.19 ROCHE SEQUENCING (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
12.19.1 COMPANY SNAPSHOT
12.19.2 REVENUE ANALYSIS (PARENT COMPANY)
12.19.3 PRODUCT PORTFOLIO
12.19.4 RECENT DEVELOPMENTS
12.2 TAKARA BIO INC.
12.20.1 COMPANY SNAPSHOT
12.20.2 REVENUE ANALYSIS
12.20.3 PRODUCT PORTFOLIO
12.20.4 RECENT DEVELOPMENTS
13 QUESTIONNAIRE
14 RELATED REPORTS
表格列表
TABLE 1 NEXT GENERATION SEQUENCING COST PER SAMPLE
TABLE 2 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA DRUG DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA AGRICULTURE & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA HOSPITAL & CLINICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 27 SOUTH AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 28 SOUTH AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 29 SOUTH AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 30 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 REST OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 11 WISE PORTFOLIO OFFERED BY MAJOR PLAYERS AND USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET IN 2021 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET
FIGURE 14 DECREASE IN COST OF PER BASE SEQUENCING
FIGURE 15 USE OF NSG IN DRUG DEVELOPMENT
FIGURE 16 REVENUE OF THE COMPANY AGILENT TECHNOLOGIES, INC.
FIGURE 17 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2021
FIGURE 18 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 20 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2021
FIGURE 22 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 24 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2021
FIGURE 26 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SNAPSHOT (2021)
FIGURE 30 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021)
FIGURE 31 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT (2022-2029)
FIGURE 34 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。


